KOCH KEVIN
Known title: President and CEOCIK: 0001185829
Associated companies
Transaction History
| EWTX | ▲ Buy | Option Exercise | 17,969 | $0 | 8/12/2026 | View on chart |
| EWTX | ▲ Buy | Option Exercise | 21,875 | $0 | 8/12/2026 | View on chart |
| EWTX | ▼ Sell | Open Market | 8,782 | $383K | 8/12/2026 | View on chart |
| EWTX | ▼ Sell | Open Market | 8,276 | $361K | 8/12/2026 | View on chart |
| EWTX | ▼ Sell | Open Market | 913 | $40K | 8/12/2026 | View on chart |
| EWTX | ▲ Buy | Option Exercise | 17,968 | $0 | 8/12/2025 | View on chart |
| EWTX | ▼ Sell | Open Market | 7,972 | $107K | 8/12/2025 | View on chart |
| EWTX | ▼ Sell | Open Market | 4,276 | $70K | 5/2/2025 | View on chart |
| EWTX | ▲ Buy | Option Exercise | 10,417 | $0 | 5/1/2025 | View on chart |
| EWTX | ▲ Buy | Option Exercise | 100 | $18 | 3/7/2025 | View on chart |
| EWTX | ▼ Sell | Open Market | 100 | $3K | 3/7/2025 | View on chart |
| EWTX | ▲ Buy | Option Exercise | 900 | $12K | 2/6/2025 | View on chart |
| EWTX | ▼ Sell | Open Market | 900 | $28K | 2/6/2025 | View on chart |
| EWTX | ▲ Buy | Option Exercise | 8,636 | $2K | 2/5/2025 | View on chart |
| EWTX | ▼ Sell | Open Market | 8,636 | $259K | 2/5/2025 | View on chart |
| EWTX | ▼ Sell | Open Market | 3,152 | $60K | 5/2/2024 | View on chart |
| EWTX | ▲ Buy | Option Exercise | 10,417 | $0 | 5/1/2024 | View on chart |
| EWTX | ▼ Sell | Open Market | 3,203 | $29K | 5/2/2023 | View on chart |
| EWTX | ▲ Buy | Option Exercise | 10,416 | $0 | 5/1/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
Edgewise Therapeutics Doses First Patient in Phase 2 Trial
Edgewise Therapeutics has dosed the first participant in its Phase 2 EQUINOX-HFpEF trial for EDG-15400, a drug intended to treat heart failure with preserved ejection fraction. This marks a key clinical milestone for the company. The stock is currently trading near its 52-week high, with analysts maintaining an average price target of $52.62.
Edgewise Therapeutics Doses First Patient in Phase 2 Trial. Edgewise Therapeutics has dosed the first participant in its Phase 2 EQUINOX-HFpEF trial for EDG-15400, a drug intended to treat heart failure with preserved ejection fraction. This marks a key clinical milestone for the company. The stock is currently trading near its 52-week high, with analysts maintaining an average price target of $52.62.